Quantcast

Latest Ataluren Stories

2014-09-17 08:29:28

SOUTH PLAINFIELD, N.J., Sept. 17, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the expansion of its global presence with the addition of key executives to leadership positions in PTC's global commercial team and the establishment of its international headquarters in Dublin, Ireland. Significant pre-launch activities are well underway as PTC prepares for the commercial launch of Translarna(TM) (ataluren) in the European Union. In August of this year,...

2014-09-10 12:28:50

However, Less Than One-Third of Duchenne Patients Are in Subpopulations That Will Benefit From New Disease-Modifying Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 10, 2014 /PRNewswire/ -- Decision Resources Group finds that the first three emerging disease-modifying therapies (DMTs)--PTC Therapeutics' Translarna (ataluren), Prosensa's drisapersen and Sarepta's eteplirsen--will likely receive regulatory approval for Duchenne muscular dystrophy (DMD) in...

2014-09-09 08:31:34

-Top-line data expected H2 2015- SOUTH PLAINFIELD, N.J., Sept. 9, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has completed enrollment of ACT DMD, the Phase 3 confirmatory trial of Translarna(TM) (ataluren) for patients with nonsense mutation Duchenne muscular dystrophy (nmDMD). Top-line data from the trial is expected in the second half of 2015 and will support further approvals globally, following European approval received earlier this...

2014-07-09 16:28:13

-French ATU Cohort and Other Named Patient Programs Authorized - SOUTH PLAINFIELD, N.J., July 9, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of a reimbursed expanded access program (EAP). PTC's EAP program is intended to make Translarna(TM) (ataluren) available to patients before commercial availability in certain countries. Where mechanisms exist and in accordance with local regulations, PTC will make Translarna available to nonsense...

2014-06-30 08:30:32

SOUTH PLAINFIELD, N.J., June 30, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of a global confirmatory Phase 3 clinical trial of Translarna(TM) (ataluren), an investigational new drug, in patients with nonsense mutation cystic fibrosis (nmCF). Nonsense mutations within cystic fibrosis are categorized as Class I mutations, a severe form of CF that results in little or no production of the CFTR protein. The Phase 3 confirmatory trial is...

2014-06-30 08:30:29

SOUTH PLAINFIELD, N.J., June 30, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it is the recipient of Parent Project Muscular Dystrophy's (PPMD) "Path to Progress" award, honoring PTC's 16 years of commitment to bring the first-ever therapy for the underlying cause of the disorder to patients with Duchenne muscular dystrophy (DMD). The award was presented at PPMD's Annual Connect Conference in Chicago, Illinois....

2014-06-24 12:27:59

CF Foundation Provided Scientific, Clinical and Significant Funding Support in Drug Development Process BETHESDA, Md., June 24, 2014 /PRNewswire-USNewswire/ -- The Cystic Fibrosis Foundation applauds the successful results of Phase 3 studies of ivacaftor (Kalydeco(TM)) in combination with lumacaftor (VX-809) for people with two copies of the F508del mutation of cystic fibrosis (CF). The results showed significant improvements in lung function and other key measures of the disease,...

2014-05-26 12:21:59

LONDON, May 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive towards Personalized Treatment and Market Growthhttp://www.reportbuyer.com/pharma_healthcare/diseases/cystic_fibrosis_therapeutics_major_developed_markets_2019_cftr_modulators_initiate_drive_towards_personalized_treatment_market_growth.htmlCystic Fibrosis Therapeutics in Major Developed Markets...

2014-05-23 08:23:53

- The first treatment for the underlying cause of Duchenne muscular dystrophy - SOUTH PLAINFIELD, N.J., May 23, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that following its request for re-examination, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the company's application for a conditional marketing authorization of Translarna(TM) (ataluren) for the treatment...

2014-05-23 08:23:51

Conference Call on Friday, May 23, 2014 at 8:30 am ET SOUTH PLAINFIELD, N.J., May 23, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will provide an update on the re-examination of its marketing authorization application to the European Medicines Agency (EMA) for conditional marketing authorization of Translarna(TM) (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy. PTC will hold a conference call at 8:30 am ET...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'